Regeneron Pharmaceuticals Faces Securities Fraud Lawsuit

Investors have been notified of a class action lawsuit filed against Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) for alleged violations of §§10(b) and 20(a) of the Securities Exchange Act.

The Schall Law Firm, which is prosecuting the case, is seeking investors to serve as lead plaintiff. The lawsuit claims that the company made false and misleading statements regarding its business and future prospects. Specifically, the allegations focus on statements made concerning the marketing and sales of its products.

The class action period covers the time during which investors purchased the company's stock purportedly based on these alleged misrepresentations. The suit seeks to recover damages for investors who suffered losses.

Investors interested in participating are advised to contact The Schall Law Firm by the specified deadline. The firm specializes in shareholder rights litigation and aims to represent all affected investors.